Mechanism of modified mRNA structure in COVID-19 vaccines for inducing neutralizing antibodies
The development of SARS-CoV-2 mRNA vaccines is closely linked to advancements in mRNA manufacturing technology. Structural modifications, such as replacing uridine with 1-methylpseudouridine (1mψ), enhance translation efficiency and help the mRNA evade immune detection. Lipid nanoparticles (LNPs) s...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Indonesian Society for Biochemistry and Molecular Biology
2024-10-01
|
| Series: | Acta Biochimica Indonesiana |
| Subjects: | |
| Online Access: | https://pbbmi.org/newjurnal/index.php/actabioina/article/view/121 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The development of SARS-CoV-2 mRNA vaccines is closely linked to advancements in mRNA manufacturing technology. Structural modifications, such as replacing uridine with 1-methylpseudouridine (1mψ), enhance translation efficiency and help the mRNA evade immune detection. Lipid nanoparticles (LNPs) serve as an effective delivery system. Vaccines like BNT162b2 and mRNA-1273 target the receptor-binding domain (RBD) of the spike (S) protein, prompting B cells to produce neutralizing antibodies that block the RBD from binding to the Angiotensin-Converting Enzyme 2 (ACE2) receptor, preventing infection. These vaccines also stimulate adaptive immune responses by activating CD4+ and CD8+ T cells, with mRNA functioning as an endogenous antigen. Antigen-presenting cells (APCs) present the vaccine antigens via major histocompatibility complex (MHC) class I and II pathways, with CD8+ T cells recognizing MHC class I and destroying infected cells, while CD4+ T cells recognize MHC class II and assist in B cell maturation and antibody production. While mRNA vaccines have proven effective in neutralizing SARS-CoV-2, challenges remain, including the decline in neutralizing antibody titers over time and the emergence of new viral variants.
|
|---|---|
| ISSN: | 2654-6108 2654-3222 |